RESEARCH TRIANGLE PARK — BioAesthetics, which provides a nipple-areolar complex graft for patients undergoing breast reconstruction, has raised roughly $4.5 million, according to a recent securities filing.
Thirty-seven investors contributed to the round, which kicked off on Sept. 9. The Triangle company is still seeking to raise another $1.7 million.
The total offering amount includes $1,235,000 in convertible notes that were converted into shares pursuant to this offering, the filing noted.
BioAesthetics was founded in 2015 as a Tulane University spin-out with the mission to improve reconstruction options for breast cancer patients after they undergo mastectomies, according to Crunchbase.
Screen shot from BioAethetics website
It is now headquartered in RTP.
The BioAesthetics’ initial product is a tissue-engineered nipple-areolar complex (NAC). This product will be provided to plastic and reconstructive surgeons as an off-the-shelf ready, acellular, NAC graft.
During the breast reconstruction phase, after a mastectomy, the surgeon would engraft the NAC graft in position onto the patient’s reconstructed breast.
The patient’s body would then use this NAC graft as a building frame to regenerate their own NAC. This patent-pending product is currently in the pre-clinical phase.
